AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Hims & Hers Health faces investigation over allegedly misleading statements.
ByAinvest
Wednesday, Jul 9, 2025 9:39 am ET1min read
• Hims & Hers Health under investigation for securities violations • Allegations of misleading statements and undisclosed information • Novo Nordisk terminates collaboration due to illegal mass compounding and deceptive marketing • FDA resolved Wegovy shortage based on meeting nationwide demand • Transitioning patients to authentic Wegovy through NovoCare Pharmacy
Hims & Hers Health, Inc. (NYSE: HIMS), a telehealth company specializing in men's and women's health, is under investigation for potential securities violations. The DJS Law Group has announced it is investigating claims on behalf of Hims & Hers investors, alleging the company issued misleading statements and failed to disclose pertinent information [1].The investigation centers on Hims & Hers' handling of GLP-1 receptor agonists, particularly semaglutide. Novo Nordisk, the manufacturer of semaglutide, terminated its collaboration with Hims & Hers due to concerns over illegal mass compounding and deceptive marketing practices [2]. The FDA has warned against unapproved ingredients and counterfeit products in compounded GLP-1s, emphasizing patient safety risks [3].
In response to the termination, shares of Hims & Hers fell by 31.7% in afternoon trading on June 23, 2025 [1]. The FDA has resolved the Wegovy shortage by concluding that Novo Nordisk is fully meeting current and projected nationwide demand for the medicine [2]. To transition patients from knock-off compounded versions to authentic, FDA-approved Wegovy, Novo Nordisk has initiated a collaboration with telehealth companies, including Hims & Hers. However, Hims & Hers has failed to adhere to the law, which prohibits mass sales of compounded drugs under the guise of 'personalization' and has been disseminating deceptive marketing that puts patient safety at risk [1].
If you are a shareholder who suffered a loss, the DJS Law Group encourages you to contact them to discuss your rights [1].
References:
[1] https://www.prnewswire.com/news-releases/hims--hers-health-inc-investigated-for-securities-fraud-violations---contact-the-djs-law-group-to-discuss-your-rights--hims-302500946.html
[2] https://www.morningstar.com/news/pr-newswire/20250709la26723/hims-hers-health-inc-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-hims
[3] https://www.pharmacytimes.com/view/novo-nordisk-drops-hims-hers-inside-the-compounded-glp-1-crisis
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet